US uninsured numbers down, PhRMA calls for reforms

7 September 2008

The Pharmaceutical Research and Manufacturers of America (PhRMA) has issued a response to the announcement by the US Census Bureau of the number of uninsured people by outlining its vision of the how to tackle the issue. The federal agency unexpectedly reported a drop in US citizens without insurance coverage at any time in the year, from 47 million (15.8%) in 2006 to 45.7 million (15.3%) in 2007. The number of uninsured children also fell, from 8.7 million (11.7%) in 2006 to 8.1 million (11%) the following year.

For federal and state authorities, the uninsured represent a double problem; on the one hand there is less likelihood of regular medical check-ups and preventative measures to reduce the risk of chronic diseases, with the additional burden of people using the emergency and public hospital system as an alternative to providing for themselves, which imposes costs on both states and the the federal government. A study commissioned by the Henry J Kaiser Family Foundation recently estimated that nearly $43.0 billion per year is spent covering uncompensated health care by providers.

Peter Pitts, president of the New York-based think-tank, the Center for Medicine in the Public Interest, noted that there is "very little discussion about who they are." Included in the ranks of the uninsured are about 20 million young people who are healthy but choose not to purchase health insurance, despite having income levels where they could do so, he said.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight